Pinato, David J.
Cortellini, Alessio
Sukumaran, Ajithkumar
Cole, Tom
Pai, Madhava
Habib, Nagy
Spalding, Duncan
Sodergren, Mikael H.
Martinez, Maria
Dhillon, Tony
Tait, Paul
Thomas, Robert
Ward, Caroline
Kocher, Hemant
Yip, Vincent
Slater, Sarah
Sharma, Rohini
Funding for this research was provided by:
Bristol-Myers Squibb
Article History
Received: 28 October 2020
Accepted: 15 March 2021
First Online: 23 March 2021
Declarations
:
: The study was reviewed and approved by the London South East NHS Ethics Committee, the UK Medicines and Healthcare products Regulatory Agency and the UK Health Research Authority (IRAS ID 244863). The study is performed in compliance with the declaration of Helsinki and the principles of Good Clinical Practice. Signed informed consent is obtained from each patient before study entry.
: Not applicable.
: DJP received lecture fees from ViiV Healthcare, Bayer Healthcare and travel expenses from Bristol Myers Squibb (BMS) and Bayer Healthcare; consulting fees for Mina Therapeutics, EISAI, Roche, Astra Zeneca; received research funding (to institution) from MSD, BMS. AC received speaker fess and grant consultancies by BMS, MSD, Roche, Astra Zeneca, Novartis and Astellas. TD has research funding from Merck Serono/Pfizer, honorarium/advisory board fees from Bayer, MSD, Sanofi Aventis, Amgen, Servier and Everything Genetic. PT received consultancy fees from SIRTEX medical. RS received research funding from Incyte, AAA, Astex, Bayer AG; consulting and advisory role: Eisai, Roche, Bayer Healthcare, SIRTEX; lecture fees: Bayer Healthcare, Falk Foundation.